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A B S T R A C T
Social anxiety disorder (social phobia) is an irrational fear of being observed and
judged by other people in various social settings. The individual is afraid that he or she
will act in a way that will be humiliating or embarrassing. It is often a chronic, dis-
abling condition that is characterized by a phobic avoidance of most social situations.
Social anxiety disorder is the most frequent anxiety disorder (10–15%) that occurs in
two subtypes – generalized and specific. It is a disorder that occurs during the adoles-
cence and reflects negatively to the quality of life of an individual. Neurobiological basis
of this disorder has not been explored yet. The disorder is frequently burdened with
comorbidity with other anxiety disorders, depression and substance-related disorders.
Only cognitive-behavioral techniques are desirable in the psychotherapeutic treatment
of the disorder and the best results are achieved in combination with pharmacotherapy.
The medicaments of choice in the treatment of social anxiety disorder are selective sero-
tonin reuptake inhibitors. Anxiolytics should be used only as a supplementary in the
acute phase. Treatment of social anxiety disorder should last at least 3 months up to one
year.
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Introduction
Social anxiety disorder (social phobia)
is an irrational fear of being exposed to
observation and judgment of other people
in various social settings. It is manifested
as a fear of public speaking, giving lec-
tures and TV statements, giving opinions
at meetings, meeting important persons,
showing knowledge and skills on exami-
nations, eating in the presence of unfa-
miliar people, etc. The person is afraid of
being embarrassed and humiliated in
public by his or her clumsiness, inexperi-
ence or ignorance. Fear occurs when an
individual is confronted with a group of
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other people in social settings in which he
or she becomes the center of their atten-
tion. If a person is forced to be in a phobic
situation, he or she experiences strong
anxiety symptoms (blushing, sweating,
trembling and speech blocks), together
with negative cognitive interpretations
(his or her performance will be judged as
stupid, inadequate and dull). The person
is aware of his or her anxiousness and ac-
companying body signs that he or she be-
lieves can easily be noticed by others; it
results in a fear from fear, which intensi-
fies the original fear, and panic may oc-
cur. Such person develops a strong antici-
pating anxiety of being confronted with
phobic situations and tries to avoid them
if it is possible. It has a negative influ-
ence on his or her social activities and re-
lationships, what results in a reduction of
a quality of life. Social anxiety disorder is
the most frequent anxiety disorder (10–
15%) and is, as such, often not recognized
as the cause of failure in school and ca-
reer, divorce, inexplicable rejections of
good business offers, asocial life, alcohol
and drug abuse or dependence, and more
other forms of life failures that are re-
sults of avoiding phobic situations. In the
best case they are recognized as persons
with mental disorders, or otherwise they
are disqualified as incompetent, inept,
less worthy, and with high chance to be-
come »the residue« of the busy, commer-
cially oriented society. Even today such
persons usually ask for medical treat-
ment of secondary mental disturbances
that have resulted from unsuccessful
avoiding behavior, and clinicians treat
general anxiety, panic disorder, depres-
sion, substance-related disorders, not rec-
ognizing social anxiety disorder as the
main cause. The problem of nonrecogni-
tion of social anxiety disorder occurs all
over the world. According to studies, so-
cial anxiety disorder occurs between
13.3% in the USA1 and 14.4% in Europe2,
but the recognition of the disorder in
practice is very low. Only about 5% of per-
sons with this disorder ask for help3, and
when they do, only a quarter of them are
diagnosed this disorder4,5.
Definition and subtypes of social anxiety
disorder
Reasonable anxiety and shyness are
normal, ubiquitous, and, for social func-
tioning, desirable feelings. Only when
their intensity is too high and it inter-
feres with social functioning, they become
psychiatric condition. Diagnostic criteria
are therefore needed for making proper
diagnosis. The criteria enable us to put a
line between general anxiety and social
anxiety disorder on one hand, and be-
tween this and other mental disorders on
the other hand. In both classifications
(DSM-IV and ICD-10) the main charac-
teristic of social anxiety disorder is a fear
of a person to be judged and observed by
other people, and he or she expects the re-
sults of such judgment to be negative and
embarrassing. In the ICD-10 public
speech in front of a mass is not considered
a phobic situation, as it is in DSM-IV, be-
cause ICD-10 specifies that the fear of be-
ing judged must be related to a small
group of people, and not to a crowd. Fur-
thermore, the DSM-IV specifies that the
disorder must represent a socio-economic
burden for a patient, or in other words, it
affects professional functioning, while
the ICD-10 does not require it. These dif-
ferences are being revised, because many
people, who live according to the limita-
tions of the disorder, have set their life
and professional goals below their pros-
pects and they seem to be relatively suc-
cessful. The ICD-10 emphasizes the im-
portance of body symptoms (blushing,
sweating, hand trembling, or urge for uri-
nation), while the DSM-IV refers only to
the symptoms of anxiety that occur in a
panic attack. Generally, the criteria in
ICD-10 are somewhat stricter. Wacker
and associates have determined that, ac-
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cording to this classification, the social
anxiety disorder occurs significantly less
often than it occurs using the DSM-
III-R6.
There are two main clinically recog-
nizable subtypes of social anxiety disor-
der today: generalized and specific. Gen-
eralized subtype is characterized by a
fear of a wide range of social situations
and specific subtype by a fear of one or
several specific social situations. The
most common fear is the fear of public
speaking (speech, lecture, TV performan-
ce etc.). Some authors (e.g. Westenberg)
consider this form of fear, without other
social fears, to be a particular subtype of
social anxiety disorder7. It is not clear if it
is only a spectrum of the intensity of this
particular disorder, or if there is a sub-
stantial difference between these subty-
pes. It has been noticed that patients
with generalized subtype, when compa-
red to those with specific subtypes, are
more often single, the disorder occurs
earlier, the patients are characterized by
a fear of interpersonal interactions, and
they have a higher rate of alcohol-related
disorders and atypical depression. Fur-
thermore, patients with generalized anxi-
ety disorder are, compared to specific
subtype, younger, less educated and with
a little chance for employment.
Sometimes it is difficult to distinguish
social anxiety disorder from agoraphobia
or panic disorder. In agoraphobia domi-
nates a fear from people as a crowd and in
social anxiety disorder there is a fear
from negative judgment by individuals in
that crowd, i.e., the fear of a person’s own
behavior, which will be judged negatively.
If there still is a doubt, the agoraphobia
should be given an advantage.
Panic disorder is not every time condi-
tioned by social situation, while in social
anxiety disorder it is always the case.
Since social anxiety disorder is chronic,
and occurs, on an average, 20 years be-
fore it is diagnosed, there is a little chan-
ce for the disorder to cease spontaneously.
Only one quarter of patients recover from
it. The chances for recovery are higher
congruently to higher education, and
higher age of a patient at the inception of
the disorder and if there are no comorbid
mental disorders. As social anxiety disor-
der occurs usually in the adolescence, a
period that is important for education
and future career, the impairment of the
quality of their life is more serious8–11.
Etiology and development of social
anxiety disorder
Social anxiety disorder occurs earlier
than any other anxiety disorder. Data
from retrospective reports of adults with
social anxiety disorder indicate that the
mean age at onset is in mid-adolescence
and that early childhood onset predicts
nonrecovery in adulthood10. However, so-
cial anxiety disorder can be detected in
children as young as 8 years of age12.
Subtypes of social anxiety disorder may
have different mean ages at onset. Ac-
cording to Mannuzza at al.8, the general-
ized subtype appeared earlier, with pa-
tient having a mean age at onset of 11
years, in contrast to a mean age at onset
of 17 years for patients with the specific
subtype. Wittchen et al. (1999) found
among adolescents (age 14–24) that so-
cial phobia was 9.5% in females and 4.9%
in males, with about one third being clas-
sified as generalized social phobias. They
also found that developmental variables
were more strongly related to generalized
social phobia then specific, including ret-
rospectively assessed high »behavioral in-
hibition« between ages 5 to 12, »long-last-
ing separation from either parent during
childhood or early adolescence« and »pa-
rental history of psychopathology«13. Ne-
vertheless, many childhood fears are
transitory; children who show social fears
retain this trait throughout late adoles-
cence. The onset of social anxiety disorder
prior to 11 years of age predicts nonre-
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covery in adulthood. Children and adults
have a similar clinical presentation. For
example, both children and adults report
the presence of virtually identical soma-
tic symptoms14. Behavioral theories point
to three key factors in the development of
the disorder: direct fear conditioning, sec-
ondary fear conditioning (learning through
observation), and verbal and nonverbal
transfer of information about phobic so-
cial situations. Retrospective reports of
adults with social anxiety disorder indi-
cate histories of parental criticism of so-
cial behaviour15. The analysis of particu-
lar social anxiety disorder subtypes shows
that the etiological factors are repre-
sented differently. In the etiology of spe-
cific subtype of the disorder the portion of
directly conditioned fear is significant,
while in generalized type of the disorder
genetic factors play the major role8. Fam-
ily can influence the onset of social anxi-
ety disorder in many ways: through di-
rect conditioning, learning by observa-
tion, transferring information, and through
biological hereditary factors. Sometimes
it is difficult to distinguish the share of
each factor in the etiology of the disorder.
For instance, some children are not in po-
sition to engage in social interactions or
they are not in position to adopt every so-
cial skill they might need. Later, in ado-
lescence, while becoming adult, it can be
a significant constellation factor in the
development of social anxiety disorder.
Some parents support their children’s
avoidance behavior in dubious social situ-
ations instead of discussing them openly,
what can induce fear in children16. Fam-
ily can influence positively and protec-
tively if insists on social skills training in
their children and helps them to manage
potentially phobic situations. It is not
clear how far parental action can directly
affect childhood social anxiety disorder,
but it is clear that if a child avoids en-
countering social situations, opportuni-
ties to learn social skills will be limited.
Parents can also influence social approach
by their verbal and nonverbal behaviours17.
Behavioral inhibition in childhood pre-
cedes social anxiety disorder. If it occurs
early and if it is conspicuous, it is an early
indication of generalized subtype. Never-
theless, it has to be mentioned, that not
every patient with generalized subtype
had exhibited behavioral inhibition dur-
ing childhood. It is very important to rec-
ognize behavioral inhibition, selective mu-
tism and other early signs of social anxiety
disorder in family and in school, because
children never initiate their treatment
due to their developmental cognitive limi-
tations. Not recognized and inadequately
treated social anxiety disorder in adoles-
cence can lead to further psychiatric com-
plications and can mask itself as depres-
sion, street fights, running away from
home, vagrancy, theft, and substance ab-
use, and it is very hard to trace it after-
wards14,18. Recent models of social phobia
tend to clearly underscore the importance
of multifactorial models. Despite being
one of the most prevalent disorders, so-
cial phobia stands as one of the least rec-
ognized, researched and treated disorder.
Future directions are suggested, includ-
ing experimental and naturalistic studies
of developmental pathways and contrib-
uting factors19,20.
Neurobiology of social anxiety disorder
Neurobiology of anxiety is complex
and it probably consists of interaction be-
tween several neuron pathways, which
use several neurotransmitting systems.
The knowledge gathered is still not com-
plete and presentations that are used
leave room for new hypotheses and dis-
coveries. Concept of »innate anxiety cir-
cuit«, although extremely simplified, is
very useful to show the model of main
components of social anxiety disorder and
possible spots that could be affected by
the available therapy methods (Figure 1).
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According to this model, persons with
social anxiety disorder perceive social sit-
uations as threatening and it activates
the innate anxiety circuit. The circuit pro-
vokes the inception of reflexive feeds on
negative cognitive judgments (to be em-
barrassed, to be incompetent). The circuit
also activates the reaction of hypothala-
mic-pituitary-adrenal axis with cha-rac-
teristic cortisol response to stress (in-
creased cortisol serum level) and stimu-
lates the autonomic system with conse-
quential characteristic blushing, sweat-
ing and trembling. These body symptoms
reflexively intensify the anxiety circuit by
setting a positive reflexive loop, which
worsens the condition further. When the
unbearable level of anxiety and excita-
tion of the autonomic nervous system is
reached, the person is forced to look for
the way out by learning how to avoid sim-
ilar situations in future. Psychotherapeu-
tic approaches, especially cognitive and
behavior therapy and social skills train-
ing are confirmed to be very efficient in
social anxiety disorder. They are directed
to modifications of behavior and cognitive
reactions in anxious conditions21,22.
-blockers are not particularly effi-
cient. Their positive effect is manifested
only in weakened peripheral autonomic
reactions, what can be used with the pur-
pose to reduce the hand tremor and other
signs of vegetative arousal in musicians,
actors, etc. The efficient psychopharma-
cological agents (benzodiazepines, irre-
versible and reversible MAOI and selec-
tive serotonin reuptake inhibitors –
SSRIs) act centrally, through innate anxi-
ety circuit, which is in the middle of con-
ceptual model of social anxiety disorder23.
According to studies that use exoge-
nous compounds to provoke anxiety, the
sensitivity of chemoreceptors in social
anxiety disorder runs between the nor-
mal and the sensitivity in panic attack.
For instance, the reaction to lactate infu-
sion in patients with social anxiety dis-
order looks more like reaction in normal
persons than reaction in patients with
panic disorder, who react on it with in-
creased anxiety24. On the other hand, pa-
tients with social anxiety disorder are
more sensitive to carbon dioxide then
normal persons, and less sensitive then
patients with panic disorder25,26. Inten-
sified perspiration, blushing and tremor
clearly show that the adrenergic system
is involved in forming the symptoms of
social anxiety disorder. This system
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Fig. 1. Concept of Innate anxiety circuit (Nutt, et al., 1998)23.
seems to be less stabile than in normal
persons and includes increased stimula-
tion of -receptors on periphery. There-
fore -blockers can remove some periph-
eral effects of anxiety, but they can re-
duce the anxiety itself only as much as it
is reflexively intensified by peripheral
-reactibility. Experimental studies show
that persons with social anxiety disorder
have a series of fine cardiovascular ab-
normalities that are characteristic for
noradrenergic instability: heart frequen-
cy more often becomes higher than nor-
mal while acting in public, and blood
pressure becomes lower then normal
while getting up, and so on27,28. There is
also plenty of evidence about the role of
GABA-dysfunction in the inception and
intensification of anxiety. Alcohol and
benzodiazepines, stimulators of GABA
neurotransmission, reduce social anxie-
ty29,30.
There is few indirect evidence of dys-
function of dopaminergic system in per-
sons with social anxiety disorder31,32. Fi-
nally, the efficiency of selective serotonin
reuptake inhibitors in treatment of the
disorder tells us that serotonin is impor-
tant in its etiology. This is also supported
by studies that point to supersensitivity
of 5HT2A-receptors32,33 and anxiolytic-
like effect of paroxetine in rats34. It is not
quite clear how the mechanism of selec-
tive serotonin reuptake inhibitors, which
reduces anxiety in persons with social
anxiety disorder, function, but postponed
effect of these agents suggests that it is a
question either of postsynaptic desensiti-
zation or of intensification of presynaptic
function. In fact, there are at least two
serotoninergic pathways involved in reg-
ulation of anxiety that have an opposite
effect. For ascendant pathway that goes
from nuclei raphe to amygdale and fron-
tal cortex, it is believed to reduce condi-
tioned fear, and for the other pathway,
from nuclei raphe to periaqueductal gray
matter it is believed to inhibit uncondi-
tioned fear. In the first pathway seroto-
nin is anxiogenic, and in another it is
anxiolytic. The effect of selective seroto-
nin reuptake inhibitors will depend on
relative importance of each pathway in
the etiology of social anxiety disorder35.
Changes in cerebral function in per-
sons with social anxiety disorder can also
be presented by neuroimaging techni-
ques. In healthy persons characteristic
changes in blood flow through the brain
can be recognized using positron emis-
sion tomography (PET) while provoking
anxiety36. It is interesting that only in
persons with social anxiety disorder
there is increased blood flow in the right
dorsolateral prefrontal cortex and left pa-
rietal cortex, the areas important for plan-
ning affective responses and for aware-
ness of the body posture37.
Comorbidity in social anxiety disorder
Social anxiety disorder is a chronic
and disabling disorder that often prece-
des other mental disorders, which dis-
semble it, and therefore clinicians have
difficulties to recognize it38. According to
one large epidemiological study39 59% of
subjects with social anxiety disorder had
secondary simple phobia, 45% had agora-
phobia, and 17% had major depression.
Besides that, 19% were alcohol depend-
ent, and 13 % were drug dependent. In
one French study of comorbidity in social
anxiety disorder it was found that in 75%
of cases it precedes depression at least a
year2. There are similar reports for ago-
raphobia2 and eating disorders40. Wit-
tchen et al. (1999) found relatively mod-
est association between specific social
phobia and other disorders, but comor-
bidities are much stronger and consistent
for generalized social phobia, especially
with regard to: Posttraumatic Stress Dis-
order (OR=17.3) and Dysthimia (OR=
13.7). Social phobia precedes 85.2% of the
comorbid substance use disorders, 81.6%
of the depressive disorders and 64.4% of
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the other anxiety disorders. Specific pho-
bia was the only comorbid condition for
which earlier ages of onset were reported
relatively frequently13. Interesting obser-
vation is that comorbidity of depression
and alcohol-related disorders in social an-
xiety disorder are more frequent in per-
sons when the disorder occurs before 15
years of age41. Suicidal risk is higher in
social anxiety disorder with comorbidity
than it is without it. Social phobia im-
pairs the person’s life, profession, family
relationships, education and career often
stronger than heavy body impairment.
Such persons get married rather infre-
quently; they get divorced and they stay
unemployed more frequently than other
persons.
Measurements of recovery from social
anxiety disorder
Recovery from social anxiety disorder
is a poorly defined concept. It is difficult
to talk about full recovery after failing a
career, missing the chances for better life,
and being burdened with comorbidity. It
is also difficult to evaluate how successful
the treatment was, because the conse-
quences of the disorder manifest in every
sphere of the person’s life. When evaluat-
ing recovery three criteria should be con-
sidered: objective – have the symptoms
and avoiding behavior disappeared or re-
duced; adaptive – have the person ob-
tained premorbid level of functioning
that releases all the persons potentials;
and subjective – does the person really
feel well (i.e. does he or she consider his
or her quality of life satisfactory). Appro-
priate standard scales are used for mea-
surement. They can be divided into those
that evaluate person’s clinical condition,
disability and quality of life. Some scales
are generic, and others are specific. They
are all based upon the questionnaire that
is filled up either by clinician or by pa-
tient. Generic scales used for measuring
the seriousness of the disorder are di-
vided into those for global measurement
(i.e. scale for Clinical Global Impressions
– CGI) and those for symptomatic mea-
surement (i.e. Hamilton Rating Scale for
Anxiety – HAM-A). Regarding specific
scales one should mention a widely used
Liebowitz Social Anxiety Scale – LSAS
that consists of 24 items, 13 of which re-
fer to public speaking situations and 11
examine social interactions. Scales for
measuring disabilities can also be generic
(Global Assessment of Functioning, Shee-
han Disability Scale) and specific (Liebo-
witz Self-Rated Disability Scale). Scales
for evaluating the quality of life are ge-
neric (WHO Quality of Life-100, Quality
of Life Inventory and Short versions for
clinicians with 36 and 12 items).
Therapeutic response to treatment
with psychotropic drugs should be evalu-
ated particularly carefully. Most often
used generic scale for measuring drug re-
sponse is CGI, where therapeutic respon-
se is considered to be significantly and
moderately better. Specific scale LSAS is
used for evaluation of the change of par-
ticular symptoms during the treatment.
Two measurement scales are particularly
suitable for evaluation of physiological
symptoms: BSPS – Brief Social Phobia
Scale and SPIN – Social Phobia Inven-
tory. Since there is no particular scale
suitable for evaluation of the recovery, it
is recommended to use several different
scales and each of them should evaluate a
particular aspect of social anxiety disor-
der: symptoms, functioning and the qual-
ity of life42,43. Specific scales are also the
Fear of Negative Evaluation Scale (FNE;
Watson and Friend, 1969) and the Social
Avoidance and Distress Scale (SAD; Wat-
son and Friend, 1969)44.
Psychotherapy of social anxiety disorder
Psychosocial therapists suggest beha-
vioral therapies in the treatment of social
phobia. These therapies are less well stu-
died in patient with social phobia than in
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those with panic disorder, agoraphobia,
or obsessive-compulsive disorder and they
are, compared to pharmacological treat-
ments, far less widely available. It is
clear from the literature on behavior and
psychology that the key factor influenc-
ing outcome of cognitive behavioral ther-
apy for patient with social phobia is expo-
sure to feared situations9. A meta-ana-
lysis of 42 treatment outcome studies
shows that the largest effect sizes were
always seen in the groups that involved
some form of exposure45. The importance
of the exposure is quite clear, but the
mechanism of its work is still not known.
Habituation is a possible explanation.
Other procedures used, in connection
with the exposure, for the treatment of
social anxiety disorder do not have an af-
fect on the outcome in any significant
degree46,47. Anxiety management strate-
gies include relaxation exercises, breath-
ing retraining and attention focusing. All
forms of behavior therapy include formal
educational components of anxiety, its
natural course, and potential etiological
factors48. There are two group cognitive
behavioral psychotherapeutic techniques:
cognitive behavioral group therapy49–52
and social effectiveness therapy (social
skills training)52,53. They both involve ex-
posure to a feared situation, but their
purpose is different. Group cognitive be-
havioral therapy is directed to correction
of cognitive mistakes, while social effec-
tiveness therapy uses social skills train-
ing in order to make phobic situations
more bearable. Group cognitive behav-
ioral therapy has the significant advan-
tage, because it is short, symptomatically
directed intervention technique. It in-
cludes an educational component about
the nature of anxiety, its various forms
and etiological factors and therapeutic
technique training that also includes ho-
mework assignments. Exposure is essen-
tial in the treatment of this anxiety
disorder54. Therapy is usually carried out
through 12 to 15 sessions of 2.5 hours
each. Cognitive restructuring is the main
component of this therapy technique. So-
cial effectiveness therapy (social skills
training) is directed to social skills train-
ing that in 28 sessions thematically
trains social skills in the period of 16
weeks, using purposeful exposure to spe-
cific situations that are phobic to patients
in well-controlled conditions52. For pa-
tients who are interested in a non-medi-
cament treatment, behavior therapy is a
rational option with proven efficiency.
However, a meta-analytic review55 shows
that exposure techniques, cognitive re-
structuring techniques and social skills
training are homogenous in their effec-
tiveness.
Pharmacotherapy of social anxiety
disorder
Main goals of pharmacotherapy in so-
cial anxiety disorder are the following: to
relieve the patient of fear and cognitive
distortions, to reduce anticipating anxi-
ety, to reduce avoiding behavior, to reduce
autonomic and physiologic symptoms of
arousal and anxiety, to improve the pa-
tient’s functioning and his or her quality
of life. In the pharmacological treatment
of social anxiety disorder following phar-
macotherapeutics have been tested: irre-
versible and reversible MAO inhibitors,
-blockers, anxiolytics and selective sero-
tonin reuptake inhibitors. Irreversible
MAO inhibitors did not prove to be suit-
able for treatment of social anxiety disor-
der due to side-effects and a series of di-
etetic restrictions the patients have to
follow during their application. In several
studies reversible selective MAO inhibi-
tor – moclobemide, which has fewer side-
effects and does not require strict dietetic
restrictions is proved to be more efficient
in treatment of social anxiety disorder
than placebo, but results were not partic-
ularly impressive56,57.
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Anxiolytic and prompt effect of ben-
zodiazepines are the cause of extensive
application in the treatment of anxiety
disorder. The effects are transient and it
is recommended to prescribe them only as
a temporary, additional therapy in acute
phase of anxiety disorder. The effect of
alprazolam in one placebo controlled stu-
dy showed poor results (alprazolam : pla-
cebo = 38% : 20%)57,58.
Better results have been achieved us-
ing clonazepam (clonazepam : placebo =
78% : 20%). It is considered today that
-blockers, in spite of their ability to par-
tially reduce body symptoms of anxiety,
are not really effective in treatment of so-
cial anxiety disorder59. Selective seroto-
nin reuptake inhibitors (SSRIs) are the
newest group of antidepressants that are
purposefully designed to act selectively
and exclusively upon serotoninergic sys-
tem. Widespread serotoninergic system
in human brain and its various roles ex-
plain various clinical applications of this
group of antidepressants. Therapeutic ef-
fect of SSRIs will depend on relative im-
portance of a damaged serotoninergic
pathway in the etiology of mental disor-
ders. It is the same for social anxiety dis-
order where SSRIs act in the way to re-
cover the natural anxiolytic activity of
serotoninergic system (see Neurobiology
of social anxiety disorder).
The most comprehensive database of
treatment with selective serotonin reup-
take inhibitors (SSRIs) refers to paro-
xetine. After two small encouraging open
studies60,61, wide multicentric and pla-
cebo controlled studies were undertaken.
850 persons with generalized anxiety dis-
order were included in three studies and
were treated with paroxetine for 12
weeks in dosages of 20, 40, 50, and 60 mg
daily. Positive effect of paroxetine to clini-
cal presentation and functioning of pa-
tients in various areas of their lives is
proved in all three studies59,62.
Information about other members of
SSRI group in the treatment of social
anxiety disorder comes from few small
well-controlled open studies or case re-
ports. Sertraline63, fluvoxamine64, fluoxe-
tine65, and citalopram66, also prove to be
efficient in the treatment of social anxiety
disorder.
Since social anxiety disorder is chro-
nic, the prevention of the relapse is par-
ticularly important. The results of a stu-
dy by Stein and associates61, in which,
after 11 weeks of treatment with paro-
xetine, they classified patients with gen-
eralized social anxiety disorder to a pa-
roxetine-group and a placebo-group, are
impressive. After 12 weeks there was
62% of relapse in a placebo-group, and
only 12% in a paroxetine-group. The au-
thors recommended pharmacotherapy
application of at least three months. In
another study, none of the patients that
were on clonazepam have relapsed after 6
months, while among those, who were
put on placebo, there was 12% of relapse
after 6 months. According to the results,
the advice would be: extended pharma-
cotherapy that should continue up to a
year after reducing the symptoms of so-
cial anxiety disorder. Indications for such
extended pharmacotherapy are: persis-
tence of significant symptoms, comorbi-
dity, early inception of the disorder, more
serious avoiding personality disorder,
and information of relapses in the past.
Since patients are most afraid of body
symptoms of anxiety, which disclose their
fear in phobic situations (blushing, trem-
bling, sweating), particular attention
should be directed to these symptoms
when following-up the efficiency of the
treatment. SSRIs are efficient in reduc-
ing these symptoms, and therefore there
is no need to combine them with -blo-
ckers. Poor therapeutic outcome can be
seen from: early inception of social anxi-
ety disorder, information of heredity,
more serious clinical presentation at the
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beginning of the treatment, comorbidity
(especially alcohol abuse or dependence)
and personality disorder (borderline, pas-
sive-dependant type)67–69. From all the
above mentioned we can conclude that
drugs of choice for social anxiety disorder
are, first of all, selective serotonin reup-
take inhibitors and highly potent anxio-
lytics. The first should be given an advan-
tage, and the second should be applied
occasionally in order to intensify anxio-
lytic effect in acute phase of the disor-
der59.
Conclusion
Social anxiety disorder is the most fre-
quent anxiety disorder (10–15%), which
occurs in two subtypes – generalized and
specific. In general practice it is still very
poorly recognized. It is a disorder that oc-
curs during the adolescence and has sig-
nificantly negative reflects on a social
life, working activity and the quality of
life of an individual. Neurobiological ba-
sis of this disorder has not been explored
yet.
The disorder is frequently burdened
with comorbidity with other anxiety dis-
orders, depression and substance-related
disorders. In psychotherapeutic treatment
of the disorder only cognitive-behavioral
techniques are desirable, and the best re-
sults are achieved by combination of
these techniques and pharmacotherapy.
The drugs of choice in the treatment of
social anxiety disorder are se- lective se-
rotonin reuptake inhibitors. Anxiolytics
should be used only as a supplementary
in the acute phase. Treatment of social
anxiety disorder should last at least 3
months up to one year.
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SOCIJALNA FOBIJA
S A @ E T A K
Socijalni anksiozni poreme}aj (socijalna fobija) je iracionalni strah od izlo`enosti
promatranju i kriti~koj procjeni drugih ljudi u razli~itim socijalnim situacijama. Osoba
se boji kako }e se svojim pona{anjem poniziti i osramotiti. To je ~esto kroni~no, onespo-
sobljavaju}e stanje karakterizirano fobi~nim izbjegavanjem ve}ine socijalnih situacija.
Socijalni anksiozni poreme}aj je naj~e{}i socijalni poreme}aj (10–15%), a javlja se u dva
podtipa: generalizirani i specifi~ni. On se pojavljuje tijekom adolescencije i negativno
se odra`ava na kvalitetu `ivota pojedinca. Neurobiolo{ka podloga ovog poreme}aja jo{
nije istra`ena. ^esto ga prate drugi anksiozni poreme}aji, depresija te ovisnost o alko-
holu i drogi. U psihoterapijskom tretmanu po`eljne su samo kognitivno-bihevioralne
tehnike, a najbolji rezultati se posti`u u kombinaciji s farmakoterapijom. Lijek izbora
su selektivni inhibitori ponovne pohrane serotonina. Anksiolitike treba koristiti samo
kao dopunsku terapiju u akutnoj fazi. Lije~enje socijalnog anksioznog poreme}aja tre-
ba trajati barem 3 mjeseca do jednu godinu.
